紫杉醇与西罗莫司洗脱支架在糖尿病患者冠状动脉介入治疗中的疗效与安全性的Meta分析  

Safety and efficacy of paclitaxel-eluting stents versus sirolimus-eluting stents in diabetes patients undergoing percutaneous coronary intervention:A Meta analysis

作　　者：王辉波[1] 杨简[1] 杨俊[1] 丁家望[1] 刘晓雯[1] 曾萍[1] 黄纬凌 杨英[1] WANG Huibol YANG Jian YANG Jun DING Jiawang LIU Xiaowen ZENG Ping HUANNG Welling YANG Ying(Institute of Cardiovascular Diseases, the First College of Clinical Medical Sciences, China Three Gorges University, Yichang, 443000, Chin)

机构地区：[1]三峡大学第一临床学院心血管病研究所,湖北宜昌443000

出　　处：《临床心血管病杂志》2016年第10期983-988,共6页Journal of Clinical Cardiology

摘　　要：目的:比较紫杉醇洗脱支架(PES)与西罗莫司洗脱支架(SES)在糖尿病患者冠状动脉介入治疗中的有效性和安全性。方法:通过Medline、EMBASE、Cochrane library数据库检索2016年5月之前所有相关英文临床随机对照试验(RCTs)。两名评价者利用Jadad评分量表独立评价纳入RCTs的质量并提取资料,评估全因死亡率、支架血栓形成(ST)率及靶病变血运重建(TLR)、靶血管血运重建(TVR)、心肌梗死(MI)、主要不良心脏事件(MACE)发生率,并用Review Manager 5.3软件进行统计分析。结果:最终分析数据来源于9个RCT试验。SES组与PES组全因死亡率、ST率以及MI发生率无统计学差异,但SES组TLR、TVR率以及MACE发生率明显优于PES组(均P<0.05)。结论:从目前临床研究看,对于糖尿病患者,SES的安全性和有效性优于PES。Objective：To investigate the safety and efficacy of paclitaxel-eluting stents（PES）versus sirolimuseluting stents（SES）in diabetes patients undergoing percutaneous coronary intervention（PCI）.Method：We systematically searched the literature through the MEDLINE,Cochrane library,and EMBASE database.Quality assessments were evaluated with Jadad quality scale.Outcomes content the rate of all-cause mortality,stent thrombosis（ST）,target lesion revascularization（TLR）,target vessel revascularization（TVR）,myocardial infarction（MI）,major adverse cardiac events（MACE）.All statistical analyses were performed using Review Manager 5.3.Result：Nine RCTs satisfying the inclusion criteria were finally analyzed.There was no significant difference in allcause mortality,ST and MI.Whereas there was a significant decrease of TLR,TVR,MACE.Conclusion：From the current clinical research,the safety and efficacy of SES is better than PES in diabetes patients undergoing PCI.

关 键 词：紫杉醇 西罗莫司 药物洗脱支架 糖尿病 META分析 

分 类 号：R541.4[医药卫生—心血管疾病]